FOLD - Amicus Therapeutics GAAP EPS of -$0.18 misses by $0.03 revenue of $86.27M beats by $3.06M
2023-05-10 07:04:12 ET
- Amicus Therapeutics press release ( NASDAQ: FOLD ): Q1 GAAP EPS of -$0.18 misses by $0.03 .
- Revenue of $86.27M (+9.6% Y/Y) beats by $3.06M .
- FY2023 Outlook : The company anticipates total Galafold revenue growth between 12 and 17% at CER driven by continued underlying demand from both switch and treatment-naïve patients, geographic expansion, label extensions, the continued diagnosis of new Fabry patients, and commercial execution across all major markets, including the U.S., EU, U.K., and Japan.
- Non-GAAP operating expense expected to be between $340 million to $360 million.
- The company is on-track to achieve non-GAAP profitability in the second half of 2023.
For further details see:
Amicus Therapeutics GAAP EPS of -$0.18 misses by $0.03, revenue of $86.27M beats by $3.06M